

PATHOLOGY OF OVARIAN HORMONES NAMELY ESTROGEN AND PROGESTERONE, PATHOLOGICAL CONDITIONS LINKED TO ESTROGEN AS WELL AS PROGESTERONE AND TREATMENT OF OVARIAN HORMONES

Muralinath.E¹, Sony Sharlet.E², Sravani Pragna.K¹, Kalyan.C¹, Vinayasree. C³, Guru Prasad.M⁴, Venkat Navven. A⁵, Sravani. K⁶, Archana Jain⁷

¹College of Veterinary Science, Proddatur, Andhra Pradesh, India

²College of Veterinary Science, Tirupati, , Andhra Pradesh, India.

³College of veterinary science, Korutla, PVNRTVU, Telangana, India.

⁴Vaishnavi microbial Phama pvt.ltd, Hyderabad, India

⁵Technical Sales Officer, Vijayawada, Andhra Pradesh, India

⁶Veterinary Officer, Nuzivedu, Andhra Pradesh, India

⁷Prof and Head, Dept. of Vety Physiology and Biochemistry, veterinary college, Jabalpur, Madhya Pradesh, India

Corresponding author: muralinathenamuri@gmail.com

ABSTRACT:-

Disruptions in the production of these hormones can result in a range of pathologies. Estrogen plays a critical role in the regulation of the menstrual cycle in many that include follicular phase, thickening of the endometrium, LH surge, negative feedback loop, menstrual bleeding, breast development, hip widening, distribution of body fat, vaginal as well as uterine development, voice changes, bone density, post menopausal effects, osteoporosis risk, fracture risk and exercise as well as diet. Progeterone plays an important role in the regulation of the luteal phase, endometrial changes, cervical mucus, menstrual cycle regulation, hormonal balance, regulation, hormonal balance, implantation as well as early pregnancy, uterine contractions and immune system. Pathology of ovarian hormones is treated due to hormone replacement therapy and lifestyle modifications. Finally it is concluded that a better diagnosis and treatment require more research work.

KEY WORDS: Estrogens, follicular phase, menstrual cycle, thickening of endometrium, LH surge, cervical mucus, menstrual bleeding, breast development, hip widening, skin changes, growth of pubic as well as axillary hair, voice changes, bone health, bone density, post menopausal effects, osteoporosis risk, hormone replacement therapy, exercise, libido, sexual function, sexual desire, vaginal lubrication, clitoral sensitivity, breast sensitivity, post menopausal effect, coagulation as well as cardio vascular effects, anti-inflammatory effect, luteal phase, ovulation cervical mucus, hormonal balance, implantation, mucus plug, anovulation and menstrual irregularities.

INTRODUCTION:-

The intricate and delicate balance of ovarian hormones plays a major role in the reproductive and overall health of women. These hormones, particularly estrogen and progesterone, are produced by the ovaries and are essential to control the menstrual cycle, supporting fertility, and maintaining various physiological processes. Whatever it may be, disruptions in the production or function of these hormones can result in a range of pathologies. In this article, we will provide an information about the pathology of ovarian hormones, shedding light on the complexities that underlie these crucial regulators of female health.

Estrogen: The Dominant Player

Estrogen is often considered the primary female sex hormone and is primarily formed in the ovaries, although it is also produced in smaller quantities in other tissues, such as the adrenal glands and fat cells. Its roles are multifaceted, extending beyond reproduction:

MENSTRUAL CYCLE REGULATION:-

Estrogen plays a critical role in the regulation of the menstrual cycle in several ways:

Follicular Phase: Estrogen levels rise during the first half of the menstrual cycle, termed as the follicular phase. It stimulates the growth and development of ovarian follicles, which contain immature eggs.

Thickening of the Endometrium: Estrogen promotes the thickening of the uterine lining (endometrium) to prepare for potential embryo implantation.

LH Surge: Rising estrogen levels provoke a surge in luteinizing hormone (LH), which results in ovulation, the release of a mature egg from the ovary.

Cervical Mucus: Estrogen influences the cervical mucus, making it more hospitable to sperm, improving the chances of fertilization.

Negative Feedback Loop: Estrogen exerts negative feedback on the hypothalamus and pituitary gland, helping to control the release of follicle-stimulating hormone (FSH) and LH.

Menstrual Bleeding: A drop in estrogen levels provokes menstruation as it destabilizes the uterine lining, resulting in the shedding of the endometrium.

Secondary Sexual Characteristics

Estrogen plays an important role in the development of secondary sexual characteristics in females during puberty and throughout their reproductive years.

Breast Development: Estrogen activates the growth and development of the mammary glands and ducts, resulting in the development of breasts.

Hip Widening: Estrogen contributes to the widening of the hips, leading to the occurrence of a wider pelvic girdle compared to males. This is important for childbirth.

Distribution of Body Fat: It influences the distribution of body fat, causing it to accumulate in a subcutaneous and gynoid pattern, often particularly around the hips and thighs.

Skin Changes: Estrogen plays a role in maintaining the elasticity and thickness of the skin, giving it a smoother appearance.

Growth of Pubic and Axillary Hair: It stimulates the growth of pubic and axillary (underarm) hair.

Vaginal and Uterine Development: Estrogen contributes to the growth and maintenance of the vaginal and uterine tissues.

Voice Changes: During puberty, it can influence the pitch of the female voice to become higher and more feminine.

Emotional and Behavioral Changes: Estrogen can influence mood, behavior, and cognitive function. It is thought to contribute to some of the emotional changes along with the menstrual cycle.

Bone Health

Estrogen plays a critical role in bone health, particularly in women.

Bone Density: Estrogen helps maintain bone density by inhibiting bone resorption (breakdown) and enhancing bone formation. It does this by controlling the activity of osteoblasts (cells that build bone) and osteoclasts (cells that break down bone).

Postmenopausal Effects: During menopause, estrogen levels decline in a significant manner. This can result in enhanced bone resorption and a higher risk of osteoporosis, a condition manifested by fragile bones.

Osteoporosis Risk: Low estrogen levels are a major risk factor for osteoporosis. Women are especially vulnerable to this condition after menopause, as estrogen levels drop.

Fracture Risk: Reduced bone density due to estrogen deficiency can result in an enhanced risk of fractures, specifically in the hip, spine, and wrist.

Hormone Replacement Therapy: Estrogen replacement therapy can be prescribed to postmenopausal women to help maintain bone density and decrease the risk of osteoporosis. Whatever it may be, it has potential side effects and should be carefully considered.

Exercise and Diet: A healthy lifestyle, along with weight-bearing exercises and a diet rich in calcium and vitamin D, can support bone health even when estrogen levels decline.

Balance with Other Hormones: Estrogen works in balance with other hormones, namely parathyroid hormone and calcitonin, to regulate calcium metabolism and bone health.

Men's Bone Health: While estrogen is typically related to the women, men also have small amounts of estrogen, and it plays a role in their bone health as well.

Libido and Sexual Function

Estrogen plays a major role in libido and sexual functions, primarily in females.

Sexual Desire: Estrogen is participated in regulating sexual desire. It contributes to the overall interest in sexual activity.

Vaginal Lubrication: Estrogen helps maintain the health of the vaginal tissues and activates the production of vaginal lubrication. This results in comfortable and enjoyable sexual intercourse.

Clitoral Sensitivity: Estrogen increases the sensitivity of the clitoris, which is a key organ for female sexual pleasure.

Breast Sensitivity: Estrogen also contributes to breast sensitivity and may enhance sexual arousal through breast stimulation.

Mood and Well-being: Estrogen can influence mood and overall well-being, which can have indirect effects on sexual desire and satisfaction.

Postmenopausal Effects: After menopause, when estrogen levels decline, some women may experience a reduction in sexual desire and changes in sexual function. Hormone replacement therapy (HRT) can be used to address these issues.

Non-Binary Effects: It's important to note that estrogen and its impact on libido and sexual functions are primarily discussed in the context of cisgender women. Its effects in transgender individuals and non-binary individuals may vary.

Estrogen's role in sexuality is complex and varies among individuals. It interacts with other hormones, psychological factors, and personal experiences to shape an individual's sexual desire and function.

Coagulation and Cardiovascular Effects

Estrogen plays a major role in coagulation and cardiovascular effects, particularly in women.

Coagulation: Estrogen has procoagulant effects, meaning it promotes blood clotting. It does this by enhancing the production of clotting factors, namely fibrinogen and factors VII, VIII, and X. This can make blood more likely to clot, which has both advantages and disadvantages.

Cardiovascular Effects:

Estrogen has several effects on the cardiovascular system:

Vasodilation: It can cause blood vessels to dilate, which can help lower blood pressure and improve blood flow.

Lipid Profile: Estrogen tends to enhance high-density lipoprotein (HDL) cholesterol, which is considered “good” cholesterol, while reducing low-density lipoprotein (LDL) cholesterol. This can be cardioprotective.

Anti-inflammatory: Estrogen has anti-inflammatory effects, which can reduce the risk of atherosclerosis and heart disease.

Risks: While estrogen has cardiovascular benefits, it is not without risks. Estrogen use, especially in high doses or in certain individuals, can enhance the risk of blood clots, stroke, and breast cancer. The balance between benefits and risks should be carefully considered in clinical practice.

Endothelial Function: Estrogen also influences the function of the endothelium, the inner lining of blood vessels. It helps maintain vascular tone and responsiveness, which is important for overall cardiovascular health.

Sex Differences: It’s important to note that the effects of estrogen on coagulation and the cardiovascular system vary between men and women. Pre-menopausal women generally have lower cardiovascular risk compared to men of the same age, in part due to estrogen’s protective effects.

Individual Variability: The impact of estrogen on coagulation and cardiovascular health can vary among individuals. Genetic factors, lifestyle, and other hormonal influences exhibit a major a role.

Pathological Conditions Related to Estrogen:

- a. Poly cystic Ovary Syndrome (PCOS): Women with PCOS often have elevated levels of estrogen, resulting in menstrual irregularities, ovarian cysts, and other complications.
- b. Endometriosis: Estrogen can fuel the growth of endometrial tissue outside the uterus, leading to pain and potential fertility issues.

PROGESTERONE:-A BALANCING ACT

Progesterone complements estrogen and is primarily formed in the corpus luteum (a temporary endocrine structure formed in the ovary after ovulation) and later by the placenta during pregnancy. Its functions include:

Menstrual Cycle Regulation

Progesterone plays a crucial role in the regulation of the menstrual cycle.

Luteal Phase Hormone: Progesterone is primarily produced by the corpus luteum, a temporary endocrine structure formed from the remnants of the ovarian follicle particularly after ovulation. It is a key hormone during the luteal phase of the menstrual cycle, which follows ovulation.

Endometrial Changes: Progesterone helps prepare the uterine lining (endometrium) for possible implantation of a fertilized egg. It makes the endometrium thicker and more vascular, providing an ideal environment for implantation.

Inhibition of Ovulation: Progesterone suppresses further ovulation during the luteal phase. This stops the release of additional eggs from the ovaries, ensuring a single egg is released per cycle.

Cervical Mucus: Progesterone thickens cervical mucus, making it more difficult for sperm to penetrate the cervix and reach the uterus. This is a natural contraceptive mechanism.

Menstrual Cycle Regulation: When the levels of progesterone decline, it provokes menstruation. This drop in progesterone signals the body to shed the uterine lining if fertilization and implantation haven't occurred.

Support for Early Pregnancy: If fertilization occurs, the corpus luteum continues to produce progesterone to support the early stages of pregnancy until the placenta takes over hormone production.

Hormonal Balance: Progesterone, along with estrogen, helps maintain hormonal balance during the menstrual cycle. The interplay between these hormones is essential for regular and healthy menstruation.

Symptoms: Changes in progesterone levels can result in various menstrual cycle-related symptoms, including PMS (premenstrual syndrome) and PMDD (premenstrual dysphoric disorder).

Pregnancy Support

Progesterone plays a critical role in supporting pregnancy.

Implantation and Early Pregnancy: Progesterone is essential for preparing the uterine lining for implantation of the fertilized egg. It helps create a suitable environment for the embryo to attach to the uterine wall.

Sustaining the Corpus Luteum: During the early stages of pregnancy, the corpus luteum, a temporary endocrine structure in the ovaries, secretes progesterone. This hormone maintains the uterine lining and supports the developing embryo until the placenta takes over its role.

Preventing Uterine Contractions: Progesterone relaxes the uterine muscles, stopping contractions that could potentially disrupt the pregnancy.

Cervical Mucus and Mucus Plug: It also thickens cervical mucus, creating a barrier that prevents the entry of pathogens into the uterus. Later in pregnancy, progesterone assists in the formation of the cervical mucus plug, further protecting the fetus.

Supporting Placental Function: As the placenta develops, it starts producing progesterone, which is critical for the continued growth and nourishment of the fetus.

Immune System Suppression: Progesterone helps modulate the mother's immune response, obstructing the immune system from attacking the developing fetus as a foreign entity.

Maintenance of Pregnancy: Throughout pregnancy, progesterone maintains the integrity of the uterine lining, ensuring a supportive environment for fetal development.

Labor Inhibition: Progesterone levels decline as labor approaches, allowing uterine contractions to begin and progress, ultimately resulting in childbirth.

Pathological Conditions Related to Progesterone:

- a. ***Luteal Phase Deficiency:*** Insufficient progesterone production during the second half of the menstrual cycle can lead to difficulties in conceiving and maintaining a pregnancy.
- b. ***Anovulation:*** When ovulation does not occur, progesterone levels remain low, influencing fertility.
- c. ***Menstrual Irregularities:*** Imbalances between estrogen and progesterone can result in irregular menstrual cycles.

The Interplay of Ovarian Hormones

It is crucial to understand that estrogen and progesterone do not act in isolation. They exert a fine-tuned, synchronized influence on the female body. An imbalance between these hormones can result in a variety of health issues, including the conditions mentioned above.

TREATMENT AND MANAGEMENT:-

The treatment of pathologies related to ovarian hormones often involves hormone replacement therapy, lifestyle modifications, and sometimes surgical interventions, based on the specific condition and its underlying causes. Management is typically tailored to each individual's unique needs and health goals.

CONCLUSION:-

The pathology of ovarian hormones is a complex, multifaceted field that significantly impacts the health and well-being of women. Understanding the roles of estrogen and progesterone, their interplay, and how imbalances can result in various conditions is essential for both healthcare professionals and the women they care for. Research in this area continues to expand our knowledge, leading to better diagnostics, treatments, and ultimately improved female health.

REFERENCES OR FURTHER READING:-

de La Motte Rouge T, Petrella MC, Michels J, et al. New drugs and targeted therapeutic agents in ovarian cancer. Bull Cancer 2009;96:1215-24. [[PubMed](#)]

- Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. *Hum Pathol* 2011;42:918-31. [[Crossref](#)] [[PubMed](#)]
- Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. *Gynecol Oncol* 2012;125:677-82. [[Crossref](#)] [[PubMed](#)]
- Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. *Curr Opin Oncol* 2010;22:473-80. [[Crossref](#)] [[PubMed](#)]
- Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. *Clin Cancer Res* 2005;11:6422-30. [[Crossref](#)] [[PubMed](#)]
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011;474:609-15. Erratum in: *Nature*. 2012 Oct 11;490(7419):298. [[Crossref](#)] [[PubMed](#)]
- Matulonis UA, Hirsch M, Palescandolo E, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. *PLoS One* 2011;6:e24433. [[Crossref](#)] [[PubMed](#)]
- Sales E, Penson RT, Sullivan LA, et al. A snapshot of personalized care: molecular diagnostics in gynecologic cancer. *J Clin Oncol* 2012.30S. abstract 5029.
- Wong KK, Tsang YT, Deavers MT, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. *Am J Pathol* 2010;177:1611-7. [[Crossref](#)] [[PubMed](#)]
- Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell* 2006;10:25-38. [[Crossref](#)] [[PubMed](#)]
- Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* 2010;330:228-31. [[Crossref](#)] [[PubMed](#)]
- Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. *Clin Cancer Res* 2011;17:2538-48. [[Crossref](#)] [[PubMed](#)]
- Tan DS, Irvani M, McCluggage WG, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. *Clin Cancer Res* 2011;17:1521-34. [[Crossref](#)] [[PubMed](#)]
- Cho KR, Shih IeM. Ovarian cancer. *Annu Rev Pathol* 2009;4:287-313. [[Crossref](#)] [[PubMed](#)]
- Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. *Lancet Oncol* 2011;12:1071-80. [[Crossref](#)] [[PubMed](#)]
- Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med* 2006;355:983-91. [[Crossref](#)] [[PubMed](#)]

- Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nat Rev Cancer* 2012;12:587-98. [[Crossref](#)] [[PubMed](#)]
- Leary A, Gore H. Incorporating bevacizumab into ovarian cancer treatment: practical considerations. *Am Soc Clin Oncol Educ Book* 2011;1:198-203.
- Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol* 2011;123:19-26. [[Crossref](#)] [[PubMed](#)]
- Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTORinhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. *J Clin Oncol* 2012;30:777-82. [[Crossref](#)] [[PubMed](#)]
- Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. *J Clin Invest* 2010;120:2858-66. [[Crossref](#)] [[PubMed](#)]
- Buckanovich RJ, Berger R, Sella A, et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). *J Clin Oncol* 2011.29. abstract 5008.
- Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. *Clin Cancer Res* 2005;11:5539-48. [[Crossref](#)] [[PubMed](#)]
- Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. *J Clin Oncol* 2010;28:1215-23. [[Crossref](#)] [[PubMed](#)]
- Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. *Invest New Drugs* 2013;31:213-29. [[Crossref](#)] [[PubMed](#)]